ArticleTranslational lung cancer research2025
Spontaneous regression of tumors post-chemotherapy in a patient with relapsed small cell lung cancer: a case report.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A lung squamous cell carcinoma demonstrating spontaneous partial regression of the primary tumor with lymph node metastasis: a case report with analysis of the tumor immune microenvironment.Translational lung cancer research · 2026Article
- Spontaneous regression of a combined large cell neuroendocrine carcinoma following bronchoscopic biopsy: A case of cytohistological discordance.Respiratory medicine case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spontaneous regression (SR) of small cell lung cancer (SCLC) is an extremely rare phenomenon, and its underlying mechanisms remain unclear. Previous reports have suggested that immune-related factors, including paraneoplastic neurological syndrome (PNS) and anti-Hu antibodies, may be involved. In this report, we present a case of SCLC that demonstrated SR after initial progression, and explore the potential immunological mechanisms, particularly focusing on changes in the tumor microenvironment. Case Description: A 78-year-old Japanese male with a significant smoking history presented with two pulmonary nodules. Surgical resection revealed non-small cell lung cancer (NSCLC) and SCLC (stage IA2). Seven months later, SCLC recurrence was confirmed via transbronchial needle aspiration (TBNA) of the subcarinal lymph nodes. First-line chemotherapy with carboplatin and etoposide resulted in a good response; however, disease progression was observed later. Second-line treatment with carboplatin and nanoparticle albumin-bound (nab)-paclitaxel was initiated, but therapy was then discontinued because of declining performance status. Unexpectedly, without further treatment, the tumor and serum gastrin-releasing peptide precursor (pro-GRP) levels began to decrease over 6 months, indicating SR. Immunohistochemical analysis revealed an increase in cluster of differentiation (CD) 8-positive T cells and a decrease in regulatory T cells in the recurrent tumor, thus suggesting immune modulation. Conclusions: This case of SCLC showed SR following chemotherapy, which was likely influenced by immune-related mechanisms. Changes in the tumor microenvironment, particularly an increase in cytotoxic T cells and a reduction in regulatory T cells, may contribute to SR. Nab-paclitaxel may contribute to the modulation of the tumor immune microenvironment. Therefore, understanding these mechanisms could provide insights into tumor immunity and potential therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.